© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Solid Biosciences Inc. (SLDB) stock surged +0.45%, trading at $8.91 on NASDAQ, up from the previous close of $8.87. The stock opened at $8.87, fluctuating between $8.64 and $8.93 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | 8.87 | 8.97 | 8.64 | 8.91 | 4.09M |
| Sep 17, 2026 | 8.94 | 8.97 | 8.60 | 8.87 | 1.19M |
| Sep 16, 2026 | 8.62 | 8.76 | 8.27 | 8.72 | 2.26M |
| Sep 15, 2026 | 8.69 | 8.69 | 8.16 | 8.37 | 1.51M |
| Sep 14, 2026 | 8.82 | 9.11 | 8.71 | 8.74 | 1.02M |
| Sep 11, 2026 | 9.21 | 9.37 | 8.65 | 8.70 | 1.11M |
| Sep 10, 2026 | 9.36 | 9.36 | 9.01 | 9.07 | 855.92K |
| Sep 09, 2026 | 9.77 | 9.95 | 9.53 | 9.54 | 646.06K |
| Sep 08, 2026 | 10.00 | 10.09 | 9.58 | 9.93 | 741.13K |
| Sep 04, 2026 | 10.20 | 10.48 | 10.20 | 10.25 | 495.3K |
| Sep 03, 2026 | 10.30 | 10.46 | 10.05 | 10.42 | 728.34K |
| Sep 02, 2026 | 9.92 | 10.44 | 9.75 | 10.29 | 894.16K |
| Sep 01, 2026 | 9.44 | 9.95 | 9.37 | 9.88 | 803.03K |
| Aug 31, 2026 | 9.73 | 9.73 | 9.37 | 9.58 | 686.62K |
| Aug 28, 2026 | 10.02 | 10.10 | 9.72 | 9.77 | 621.52K |
| Aug 27, 2026 | 10.03 | 10.27 | 9.89 | 10.13 | 988.93K |
| Aug 26, 2026 | 9.84 | 9.85 | 9.60 | 9.72 | 594.13K |
| Aug 25, 2026 | 9.33 | 9.90 | 9.33 | 9.89 | 1.26M |
| Aug 24, 2026 | 9.28 | 9.28 | 8.86 | 9.16 | 1.11M |
| Aug 21, 2026 | 9.34 | 9.66 | 9.23 | 9.30 | 790.35K |
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
| Employees | 121 |
| Beta | 2.44 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |